<DOC>
	<DOCNO>NCT01295099</DOCNO>
	<brief_summary>To clarify mechanism Keloid scar formation . Elucidate action therapeutic value 5-FU Keloid scar treatment Identify genetic link Keloid scar formation . Quantify psychological/social impact keloid scarring patient</brief_summary>
	<brief_title>Keloid Scarring : Treatment Pathophysiology</brief_title>
	<detailed_description />
	<mesh_term>Keloid</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Adult ( &gt; 18 year old ) . Keloid scar present . Able understand give inform consent . Patients give informed consent donate keloidal nonaffected skin redundant procedure ( i.e . BBR , Abdominoplasty ) . Patients strong familial pedigree keloid scar formation . Open wound proximity lesion Infected lesion Pregnant planning pregnancy near future Lactating ( Breast Feeding ) Abnormal renal liver function test Atrophic scar Patient 18 year age Immunocompromised OR immunosuppressed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>scar formation</keyword>
	<keyword>5-FU</keyword>
	<keyword>genetic link</keyword>
	<keyword>psychological impact</keyword>
	<keyword>social impact</keyword>
</DOC>